R-R intervals Variability and continuous Blood Pressure testing

Real-Time Monitor of Heart Rate Variability analysis

Intellewave HRV system is a fully automated cardiac monitoring device that provides a quantitative assessment of Heart Rate Variability analysis. IntelleWave testing allows physicians to monitor physiological activity and assess the state of a patient's autonomic function through analysis of Spectral Function Components of R-R intervals Variability. HRV testing with IntelleWave system enables physicians to detect specific types of autonomic dysfunction that may be linked to a multitude of clinical diagnoses. Additionally, IntelleWave is a tool for overall, general assessment of a patient's physiology, and as such, provides a comprehensive, in-depth patient evaluation, often missing in standard medical practice. Such an ability to assess one's physiology determines the wide range of IntelleWave's clinical applications and distinguishes it favorably from all other diagnostic devices based on HRV analysis.  Moreover, IntelleWave can monitor HRV activity by providing of “real-time” quantitative assessment of spectral function components of HRV (HF and LF). Note: all clinical correlations of HRV analysis data are performed solely by a physician. IntelleWave system's proprietary algorithm (US Patent 2012018916) uses novel artificial intelligence techniques to differentiate between high frequency (HF) and low- frequency (LF) components of spectral function. This unique representation of test results allows physicians to recognize up to 81 different variations of the relationship between LF and HF components.

Intellewave also can provide "real-time" up to 24hr quantitative HRV assessment. The list of the potential application by this regime is next:
- Monitor HRV components during anesthesia.
- Monitor HRV components in intensive care to see the effectiveness of
the medication.
- Monitor HRV components by implantable devices.
- Using for sleep studies to see the difference between "sleep
time"  and "awake time".

F8

Clusterization of the relationship between SNS and PSNS status

This technological breakthrough is achieved by using proprietary algorithms and a new approach based on one of the leading theories of Artificial Intelligence - Marvin Minsky's Frame Theory. Intellewave objectively and reliably evaluates the state of ANS in "real-time" (up to 24 hours) as well as during Orthostatic test and Valsalva maneuver combined with Deep Breathing. Due to its highly sophisticated HRV analysis, Intellewave is the only system that enables quantification of 81 ANS states with a corresponding qualitative description for each one.
Clusterization of the Autonomic Nervous System's States

History of product

 

The product was originally conceived by its developer Dr. Alexander Riftine for the needs of the Navy. Specifically, the product was to meet the need for objective testing of the general health and special fitness conditions of the Navy pilots, underwater divers, navy seals and other marine personnel.

Between 1981 and 1982 the first trial version of the product was developed based on the Time Domain and Auto-regression Function approach. By 1982 it became clear that the Time Domain approach was fundamentally flawed as it didn't reflect the internal structure of the heart rhythm. It was also revealed that the probability of erroneous assessments was no less than 30%, which was unacceptable.

In 1982 a new trial version was developed based on the Frequency Domain approach.

In 1982 a massive data collection effort was started, and by the summer of 1986 12000 samples of Orthostatic test data and 700 samples of Stress test data were collected and analyzed. One of the results of this analysis was a proprietary Classification of the Transitional Periods during the Orthostatic test, developed in 1986.

To provide a meaningful and systematic interpretation for his entire collection of data, Dr. Riftine started searching for a fundamentally new methodology that would be more comprehensive and precise in measuring the individual's current physical/physiological state as well as a health resource and genetic ability.

In the first part of 1987, Dr. Riftine formulated a novel theory for the quantitative assessment of the individual's functional state utilizing HRV methodology. This theory was based on Dr. Riftine's original ideas in the field of Bio-medical Cybernetics and Normal Physiology. The practical applications of the theory - specifically, its proprietary algorithms for the quantitative assessment of the individual's functional state - were developed on the basis of Marvin Minsky's Frame Theory.

The first product based on Dr. Riftine's new theory, Health-Express, was developed by 1988. It provided the assessment of the level of Physical Fitness. The marketing campaign for Health-Express was launched in 1988.

In 1992 a new product, Nerve-Express, was launched. Nerve-Express is the first product to provide an automatic quantitative assessment of the Autonomic Nervous System(ANS).

Nerve-Express solved a challenging problem of subdividing the Spectral Function of R-R intervals variability into two parts:

- High Frequency (which correlates with Parasympathetic activity 95% of the time) and
- Low Frequency (correlates with Sympathetic activity up to 70% of the time).

In the past, the division line (between PNS and SNS) was found at a mean Frequency of 0.15 Hz (for an average healthy person). However, for each individual, this transition point varies.
Nerve-Express was able to come up with a calculation which is unique to any given person.
In addition, Nerve-Express also dealt with the problem of reducing all possible variations of multiple parameters (20-30) into a quantitative relationship between only two parameters: SNS and PSNS.
Nerve-Express is the first and only system to solve this problem of SNS-PSNS quantification. This technological breakthrough is achieved by the application of Dr. Riftine's proprietary algorithms.

The original and all subsequent releases of Nerve-Express include Health-Express.

From 1997 to 2000 a validation study of Nerve-Express was conducted by J. Thomas Bigger, Jr., M.D., Head of Research Holter Laboratory, at Columbia University College of Physicians and Surgeons.

In 1998 a "real-time" (up to 48 hours) Autonomic assessment was added to Nerve-Express.

In May 2001 the European registration (CE mark) for Nerve-Express was granted and in August 2001 Nerve-Express was launched on the European market.

In 2003 another test was added - the Valsalva maneuver combined with Deep Breathing.

2004 it becomes compatible with ambulatory Holter-Monitor for 24 hours Autonomic assessment
with a possibility to see the one-page difference between "sleep" time and
"awake" time.

2008 it becomes compatible with PBI PC ECG device which enables to see one lead ECG
on the screen and printout afterward any part of ECG.

2010 Patent "Quantitative assessment of Autonomic function based on Heart Rate Variability" is granted.

2010 Wireless Bluetooth device Zephyr HxM added to the list of compatible devices.

2011 Corscience, GMBx ECG wireless Bluetooth device added to the list of devices.

Alexander Riftine

President & CEO

Include a short bio with an interesting fact about the person.

Vic Pershen

Technical Support

Include a short bio with an interesting fact about the person.

Contact Our Technical Support

Intellewave company provides technical support

Monday - Friday
10:00 am - 6:00 pm